In exome-wide analysis in UK Biobank data, rare loss-of-function (LOF) variants in BRCA1 and BRCA2 were associated with earlier (2.63 and 1.53 years respectively) ANM compared with non-carriers, while LOF variants in CHEK2 were associated later ANM (3.49 years difference) [14]. This evidence concerns the gene BRCA2 and nemaline myopathy 5.